VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | PROOF 301: infigratinib in advanced CCA

VJOncology is committed to improving our service to you

Milind Javle

Milind Javle, MD, of MD Anderson Cancer Center, Houston, TX, outlines the rationale and trial design of PROOF 301 (NCT03773302), a Phase III study investigating first line infigratinib in cholangiocarcinoma (CCA) patients with FGFR2 gene fusions/translocations. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter